In this study, the investigators plan to administer neoadjuvant durvalumab and adjuvant durvalumab to the operable NSCLC patients (resectable stage IIA~IIIB) regardless of PD-L1 status.~Durvalumab 1500mg IV will be administered once prior to surgery. Within 1-8 weeks after completion of durvalumab, patients will undergo surgery. Regardless of MRD status, patients will receive adjuvant treatment of durvalumab 1500mg IV q3 weeks with SoC platinum-based chemotherapy for a total of 4 cycles.~** Adjuvant chemotherapy will be based on standard of care treatment: navelbine 20mg/m2 (D1, 8) and cisplatin 80mg/m2 (D1) (q3w x 4 cycles).~Thereafter, patients will be administered with adjuvant durvalumab 1500mg IV q4 weeks for 10 cycles
This study is phase II, open label, clinical trial of durvalumab to identify immune dynamics in operable non-small cell lung cancer.